Study Title

99mTc-PSMA-I&S in Patients With Prostate Cancer: An Exploratory Biodistribution Study With Histopathology Validation

Study Details

Description:

This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.

Sponsor:

Jonsson Comprehensive Cancer Center (UCLA)

Drug Details

Isotope(s):
    TECHNETIUM-99m
    Radioisotope: Tc-99m
    Theranostic Role: SPECT Imaging
    T1/2 (Half-Life): 6 Hours
    Decay Mode: GAMMA
    Energy: 140 keV (89.1%)
    Range: N/A
    Decay Daughters: Tc99
    Status: FDA Approval: First in 1980’s
  • TECHNETIUM-99m
Target(s):
  • PSMA

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468